Lenalidomide versus Thalidomide or Bortezomib as maintenance regimen for non-transplant patients with multiple myeloma: multi-center real world experiences in China

被引：0
|
作者：
Zhuang, Zhe [1 ]
Shi, Lei [2 ]
Tian, Ying [3 ]
Zou, Dongmei [4 ]
Feng, Ru [5 ]
Dong, Fei [6 ]
Ma, Yanping [7 ]
Yu, Hong [8 ]
Tian, Wei-wei [9 ]
Liu, Shuangjiao [1 ]
Ma, Liang-Ming [10 ]
Fu, Rong [8 ]
Jing, Hongmei [6 ]
Liu, Hui
Sun, Wanling [4 ]
Chen, Wenming [3 ]
Wu, Yin [3 ]
Bao, Li [2 ]
Zhuang, Junling [1 ]
机构：
[1] Chinese Acad Med Sci, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China
[3] Capital Med Univ, Dept Hematol, Beijing Chao Yang Hosp, Beijing, Peoples R China
[4] Capital Med Univ, Dept Hematol, Xuanwu Hosp, Beijing, Peoples R China
[5] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Dept Hematol, Beijing, Peoples R China
[6] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China
[7] Shanxi Med Univ, Dept Hematol, Hosp 2, Taiyuan, Peoples R China
[8] Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin, Peoples R China
[9] Shanxi Med Univ, Dept Hematol, Shanxi Bethune Hosp, Taiyuan, Peoples R China
[10] Shanxi Med Univ, Hosp 2, Dept Hematol, Taiyuan, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-141
引用
收藏
页码：S112 / S113
页数：2
相关论文
共 50 条
  • [21] Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
    Mateos, Maria-Victoria
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Gutierrez, Norma
    Teruel, Ana-Isabel
    de Paz, Raquel
    Garcia-Larana, Jose
    Bengoechea, Enrique
    Martin, Alejandro
    Diaz Mediavilla, Joaquin
    Palomera, Luis
    de Arriba, Felipe
    Gonzalez, Yolanda
    Hernandez, Jose-Mariano
    Sureda, Ana
    Bello, Jose-Luis
    Bargay, Joan
    Penalver, Francisco-Javier
    Ribera, Jose-Maria
    Martin-Mateos, Maria-Luisa
    Garcia-Sanz, Ramon
    Cibeira, Maria-Teresa
    Martin Ramos, Maria-Luisa
    Vidriales, Maria-Belen
    Paiva, Bruno
    Montalban, Maria-Angeles
    Lahuerta, Juan-Jose
    Blade, Joan
    San Miguel, Jesus-Fernando
    LANCET ONCOLOGY, 2010, 11 (10): : 934 - 941
  • [22] The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction: An Analysis of Real World Data
    Cherniawsky, Hannah
    Sandhu, Irwindeep
    Chu, Michael P.
    Hewitt, Joanne D.
    Ismail, Ismail
    Belch, Andrew
    Pilarski, Linda M.
    Nikitina, Tatiana
    Venner, Christopher P.
    BLOOD, 2017, 130
  • [23] COMPARISON OF RESPONSE DURATION (RPD) AFTER THALIDOMIDE, BORTEZOMIB AND LENALIDOMIDE ADMINISTRATION TO MULTIPLE MYELOMA (MM) PATIENTS; A SINGLE CENTER EXPERIENCE
    Kyrtsonis, M. C.
    Nikolaou, E.
    Maltezas, D.
    Koulieris, E.
    Iliakis, T.
    Sarris, K.
    Vyniou, E.
    Vardounioti, I.
    Efthymiou, A.
    Bitsani, K.
    Karali, V.
    Pessach, I.
    Bartzis, V.
    Tzenou, T.
    Dimou, M.
    Vassilakopoulos, T.
    Angelopoulou, M.
    Tsaftaridis, P.
    Panayiotidis, P.
    HAEMATOLOGICA, 2014, 99 : 646 - 646
  • [24] Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)
    Hyeon-Seok Eom
    Yeo-Kyeoung Kim
    Joo-Seop Chung
    Kihyun Kim
    Hyo Jung Kim
    Ho Young Kim
    Jong-Youl Jin
    Young-Rok Do
    Suk-Joong Oh
    Cheolwon Suh
    Chu-Myong Seong
    Chul Soo Kim
    Dong Soon Lee
    Jae Hoon Lee
    Annals of Hematology, 2010, 89 : 489 - 497
  • [25] Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)
    Eom, Hyeon-Seok
    Kim, Yeo-Kyeoung
    Chung, Joo-Seop
    Kim, Kihyun
    Kim, Hyo Jung
    Kim, Ho Young
    Jin, Jong-Youl
    Do, Young-Rok
    Oh, Suk-Joong
    Suh, Cheolwon
    Seong, Chu-Myong
    Kim, Chul Soo
    Lee, Dong Soon
    Lee, Jae Hoon
    ANNALS OF HEMATOLOGY, 2010, 89 (05) : 489 - 497
  • [26] Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)
    Ishida, Tadao
    Ozaki, Shuji
    Kimura, Hideo
    Kubo, Koumei
    Sunami, Kazutaka
    Takezako, Naoki
    Fujita, Hiroyuki
    Hayashi, Toshiaki
    Kiguchi, Toru
    Kobayashi, Takeshi
    Yamamoto, Satoshi
    Takamatsu, Hiroyuki
    Kosugi, Hiroshi
    Ohta, Kensuke
    Sakai, Rika
    Handa, Hiroshi
    Hisatomi, Takashi
    Abe, Yu
    Sasaki, Ko
    Omoto, Eijiro
    Murakami, Hirokazu
    Shimizu, Kazuyuki
    BLOOD, 2017, 130
  • [27] Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience
    Yang, Chloe
    Jiang, Haiyan
    Masih-Khan, Esther
    Chen, Christine I.
    Prica, Anca
    Reece, Donna
    Tiedemann, Rodger
    Trudel, Suzanne
    Kukreti, Vishal
    BLOOD, 2017, 130
  • [28] Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment
    Saeed, Nabiha
    Khan, Zurrya
    Jehanzeb, Hamzah
    Shaikh, Taha
    Shaikh, Usman
    Adil, Salman N.
    Madni, Varisha
    Fatima, Hania
    Abiha, Umm E.
    Ali, Natasha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [29] Randomised, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone Followed by Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide and Dexamethasone Followed by Lenalidomide and Dexamethasone Maintenance in Patients With Newly Diagnosed Multiple Myeloma Not Intended for Transplant: CARTITUDE-5
    Dytfeld, Dominik
    Dhakal, Binod
    Agha, Mounzer
    Manier, Salomon
    Delforge, Michel
    Kuppens, Steven
    Afifi, Salma
    Deraedt, William
    Taraseviciute-Morris, Agne
    Schecter, Jordan M.
    Gilbert, Jane
    Yalniz, Fevzi
    Florendo, Erika
    Pacaud, Lida
    Hungria, Vania
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 122 - 123
  • [30] Bortezomib-Thalidomide-Dexamethasone (VTD) As Salvage Treatment in Patients with Multiple Myeloma Candidates for Transplantation in the Real World
    Vasquez, Jule
    Quintana, Shirley
    Lopez, Lourdes
    Alcarraz, Cindy
    Villena, Marco
    Neciosup, Silvia
    Mas, Luis
    Gomez, Henry
    BLOOD, 2017, 130
12345